Founded in 2016, Calyxo operates in medical devices. The latest valuation stands at $684.6M. Its shares do not trade on a public exchange.
One company valuation: $684.6M, dated Apr 2026.
Calyxo, founded in 2016 and based in Pleasanton, California, is a medical device company focused on improving care for patients with kidney stones. Its CVAC System is described as the world's first all-in-one kidney stone treatment, built to let urologists remove stones safely, effectively and efficiently.
The company brings together medtech professionals with deep expertise in urology and a track record of building and scaling medical technologies, aiming to help physicians achieve unrivaled clinical outcomes for patients.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Calyxo.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Calyxo availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Calyxo included.
No. Calyxo is a private company; its shares do not trade on a public exchange.
The last valuation is $684.6M.
Lead investors for each round are in the funding timeline.
The closest medical devices peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
